Show Summary Details
Page of

Maternal malignancy 

Maternal malignancy
Maternal malignancy

Harini Narayan

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 16 June 2021

Cancer in pregnancy is rare, but with survival rates generally greater than 75% and easier access to fertility treatments, more cancer survivors now consider pregnancy, particularly with greater access to fertility treatments. This chapter presents antenatal management of the most common malignancies with relevance to pregnancy including cancers of the breast, cervix, leukaemia, lymphoma, melanoma, thyroid, ovary, and colon. Multidisciplinary management required when malignancy is diagnosed during pregnancy or pregnancies in cancer survivors, chemo- and radiotherapy, and possible effects on fetal development and long-term outcomes, pregnancy outcomes and prognosis are discussed. The special situations of pregnancy in cancer survivors previously treated with anthracycline as well as conception while on tamoxifen are highlighted. Recommended interval from the end of cancer treatment to conception in individual malignancies is discussed. The fact files, care pathways, and patient information are underpinned by national guidelines and up-to-date literature, including breast cancer addressed as a separate topic.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.